Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 21,446 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 21,446 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $3.65, for a total value of $78,277.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.90, for a total value of $99,446.10.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total transaction of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.04, for a total transaction of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The stock was sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Trading Down 11.1%

Shares of Galectin Therapeutics stock opened at $3.45 on Wednesday. The firm’s 50 day simple moving average is $5.30 and its two-hundred day simple moving average is $4.39. The firm has a market capitalization of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03. Galectin Therapeutics Inc. has a 12-month low of $1.07 and a 12-month high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts predict that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GALT shares. HC Wainwright raised their price objective on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Galectin Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.00.

Galectin Therapeutics News Roundup

Here are the key news stories impacting Galectin Therapeutics this week:

• Neutral Sentiment: Regulatory disclosure: multiple Form 4 filings were submitted this week reporting the insider sales; investors can review the filings for exact timestamps and amounts. Form 4 – Jamil
• Negative Sentiment: CEO Joel Lewis sold a total of 84,000 shares across Jan. 2, 5 and 6 (average prices ~$4.20, $3.91, $3.58), raising roughly $320k and trimming his stake by a few percent. Large CEO sales can be perceived negatively by the market. Form 4 – Joel Lewis
• Negative Sentiment: CFO Jack W. Callicutt sold 60,000 shares over the same period (average prices ~$4.20–$3.67), generating roughly $233k; one filing shows his reported ownership dropping by ~72.8% after a transaction. Large, repeated sales from the CFO amplify concern about insider sentiment or liquidity needs. Form 4 – Jack Callicutt
• Negative Sentiment: Insider Khurram Jamil sold 60,000 shares across Jan. 2–6 at prices between ~$4.20 and $3.65 (~$232k total). Multiple insiders selling similar-sized blocks in the same window increases perceived downside risk. Form 4 – Khurram Jamil
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into Galectin, which may lead to litigation or heightened scrutiny and typically weighs on share price until resolved. INVESTOR ALERT: Pomerantz Investigates GALT

Institutional Trading of Galectin Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after acquiring an additional 19,316 shares during the period. Nuveen LLC purchased a new position in shares of Galectin Therapeutics during the 1st quarter valued at approximately $34,000. Geneos Wealth Management Inc. lifted its stake in shares of Galectin Therapeutics by 8.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock valued at $516,000 after purchasing an additional 34,300 shares during the period. Retirement Guys Formula LLC boosted its holdings in Galectin Therapeutics by 2.7% during the second quarter. Retirement Guys Formula LLC now owns 159,593 shares of the company’s stock worth $337,000 after buying an additional 4,250 shares in the last quarter. Finally, Truist Financial Corp purchased a new stake in Galectin Therapeutics during the second quarter worth $143,000. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.